
Bristol Myers Squibb Company (NYSE:BMY – Free Report) – Zacks Research increased their Q3 2027 earnings per share estimates for shares of Bristol Myers Squibb in a research report issued on Wednesday, November 11th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings per share of $1.74 for the quarter, up from their previous estimate of $1.55. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.46 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.41 EPS, Q1 2028 earnings at $1.36 EPS, Q2 2028 earnings at $1.25 EPS and Q3 2028 earnings at $1.16 EPS.
BMY has been the topic of several other reports. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Bank of America reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Friday, October 30th. Citigroup reaffirmed a “neutral” rating and set a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Jefferies Financial Group reiterated a “buy” rating and issued a $76.00 price objective on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Finally, Guggenheim reiterated a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and an average target price of $65.46.
Bristol Myers Squibb Trading Down 0.1%
NYSE BMY opened at $63.39 on Monday. The stock has a market capitalization of $129.57 billion, a P/E ratio of 14.06, a P/E/G ratio of 0.33 and a beta of 0.20. The business has a 50 day simple moving average of $61.90 and a 200 day simple moving average of $60.31. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. Bristol Myers Squibb has a one year low of $45.26 and a one year high of $68.64.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. During the same period in the previous year, the business earned $1.63 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year.
Bristol Myers Squibb Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s payout ratio is presently 55.88%.
Insider Transactions at Bristol Myers Squibb
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Julia A. Haller sold 3,800 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the transaction, the director owned 30,279 shares in the company, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.05% of the company’s stock.
Hedge Funds Weigh In On Bristol Myers Squibb
Institutional investors have recently modified their holdings of the company. Blue Chip Partners LLC bought a new position in shares of Bristol Myers Squibb in the 3rd quarter worth $212,000. Jump Financial LLC acquired a new stake in Bristol Myers Squibb in the 3rd quarter valued at $4,773,000. Flputnam Investment Management Co. grew its position in Bristol Myers Squibb by 3.1% in the 3rd quarter. Flputnam Investment Management Co. now owns 243,237 shares of the biopharmaceutical company’s stock valued at $15,178,000 after purchasing an additional 7,226 shares during the period. Perennial Investment Advisors LLC increased its stake in Bristol Myers Squibb by 20.1% during the 3rd quarter. Perennial Investment Advisors LLC now owns 5,722 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 957 shares in the last quarter. Finally, L2 Asset Management LLC increased its stake in Bristol Myers Squibb by 58.7% during the 3rd quarter. L2 Asset Management LLC now owns 71,517 shares of the biopharmaceutical company’s stock valued at $4,463,000 after purchasing an additional 26,444 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.
Top Bristol Myers Squibb Stories
Here are a few of the latest stories about BMY:
- Positive Sentiment: Bristol Myers is working to expand Camzyos’ reach, while Eliquis remains an important contributor to its cardiovascular franchise. Sustained growth in these products could help support revenue. Can BMY Sustain Growth in Its Cardiovascular Franchise?
- Neutral Sentiment: The company plans to unify research and development under one structure, aiming to bring scientific and clinical teams together to speed development and use new technologies. The departure of research chief Robert Plenge adds transition risk, so the impact will depend on execution. BMS sets unified research and development structure for 2027
- Negative Sentiment: Zacks Research cut several earnings forecasts, including FY2026 EPS to $6.44 from $6.86 and FY2028 EPS to $4.77 from $5.21; it also reduced its Q4 2026 and Q2 2027 estimates. These revisions point to a softer earnings outlook, although the firm maintained a Hold rating. Bristol Myers Squibb analyst estimates
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
